Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05123807 · ClinicalTrials.gov registry record · Phase 2

Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)

A Phase 2 study of Ovarian Cancer, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
30
Enrollment target
1
Study location

NCT05123807: Recruiting Phase 2 study of Ovarian Cancer, sponsored by M.D. Anderson Cancer Center.

NCT05123807 is a Phase 2 study of Ovarian Cancer that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 30 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05123807, a Phase 2 study of Ovarian Cancer, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The primary objective is to estimate overall survival after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer

Conditions Studied

Ovarian Cancer

Interventions

  • OTHER Cytoreductive surgery

Study Locations (1)

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-01-07
Est. Completion 2027-02-02
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

What NCT05123807 shows while recruiting

NCT05123807 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Cytoreductive surgery is the first listed.

NCT05123807 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT05123807 about?

NCT05123807 is a clinical study titled "Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)". The primary objective is to estimate overall survival after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer

What is the current status of trial NCT05123807?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2022-01-07. Estimated completion is 2027-02-02.

What conditions does trial NCT05123807 study?

This clinical trial studies the following conditions: Ovarian Cancer.

What interventions are being tested in trial NCT05123807?

The interventions under investigation include: Cytoreductive surgery (OTHER).

Who is sponsoring clinical trial NCT05123807?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05123807 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05123807's enrollment target sits among peer trials

30 252nd of 322 higher than 62 of 322 other Ovarian Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05123807

Source: ClinicalTrials.gov NCT05123807, the US trial registry maintained by the National Library of Medicine. NCT05123807 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.